Dave & Buster's Breaks Ground on First Location in the Philippines at Opus Mall
The groundbreaking ceremony, held in partnership with local franchisee The Bistro Group, welcomed company executives, local officials, and community leaders. This flagship venue is poised to become a premier destination for immersive entertainment, dynamic sports viewing, and craveable American fare.
"This is more than a groundbreaking—it's a landmark moment in our international story," said Antonio Bautista, Chief International Development Officer for Dave & Buster's. "With the strength of our partnership with The Bistro Group, we're bringing an exciting new concept to Manila that delivers fun, flavor, and unforgettable experiences."
Jean Paul Manuud, President of The Bistro Group, added: "Dave & Buster's is a game-changing brand. We're proud to launch this first-of-its-kind experience in the Philippines where great food, cutting-edge games, and community come together."
The Manila location will feature a curated mix of American classics and localized dishes, state-of-the-art games, and multi-use spaces for events and sports fans. This opening kicks off a broader multi-unit development plan in the country.
This milestone reinforces Dave & Buster's commitment to international growth, with additional venues planned this year in India (second location), Australia, Mexico, and the Dominican Republic. The brand currently operates over 220 locations across North America and is now expanding across five continents.
About Dave & Buster'sFounded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc. operates leading entertainment and dining venues across North America under the Dave & Buster's and Main Event brands. For more information, visit www.daveandbusters.com.
About The Bistro GroupThe Bistro Group is a leading restaurant operator in the Philippines, known for introducing iconic international brands like TGIFridays, Denny's, Texas Roadhouse, and Hard Rock Café to the local market. For more information, visit www.bistro.com.ph.
View original content:https://www.prnewswire.com/apac/news-releases/dave--busters-breaks-ground-on-first-location-in-the-philippines-at-opus-mall-302462463.html
SOURCE Dave & Buster's
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
11 minutes ago
- Business Insider
AI could be the US's secret weapon in the race to mine more minerals — if it can prove itself
The US is scrambling to reduce its reliance on foreign sources of critical minerals. The raw materials are essential inputs for modern technology. Smartphones, 5G networks, and military weapons like fighter jets are built using these materials, and they continue to be used to spur innovation. Lithium powers electric vehicle batteries, copper keeps data centers running, and silicon forms the foundation of semiconductors. Demand is rising fast, with the global critical minerals market projected to reach nearly $500 billion by 2030, said Kings Research, a market research firm. Yet the US still relies heavily on imports. As of 2024, the country imported 100% of 12 out of 50 designated critical minerals, including graphite, manganese, and gallium, according to the United States Geological Survey, many of which come from China. Now, under the second Trump presidency, the US is pushing to reestablish its dominance in mineral production. The administration has made domestic manufacturing a national priority, issuing an executive order to boost mining on American soil and imposing 50% tariffs on imported metals like steel and aluminum. Rebuilding domestic mineral supply could strengthen the economy and improve national security. But it could also lead to supply gaps, potentially driving up the cost of materials that power innovation. To prevent bottlenecks, startups and legacy tech companies are turning to artificial intelligence. Their AI tools promise to speed up mineral discovery and reduce supply chain risks in a volatile geopolitical climate. But in a highly regulated industry where progress is slow, some experts question whether AI can deliver on its promises. Startups are racing to reshape mineral exploration Startups are betting on AI to discover new mineral deposits — and some are seeing early results. Earth AI uses predictive software and proprietary drilling hardware to find, verify, and sell multi-billion-dollar mineral projects. Its algorithms are trained on decades of historical data from Australia, including past successes and failures of mineral discovery, to pinpoint hydrothermal systems: heated, mineral-rich waters likely to hold valuable deposits. After identifying a promising site, the company drills using its own rigs and analyzes rock samples to confirm the presence of metal. Once proven, the site is sold to larger mining firms. Earth AI said it has a success rate of 75% — far above the industry average of less than 1%. Over the last 12 months, the company said it has already made three discoveries in Australia, one of which is indium, a rare metal used in touchscreens and semiconductors for AI hardware. It's also discovering untapped reserves rich with minerals. In late July, Earth AI's software identified a massive underground trove of nickel and palladium in the east coast of Australia the company will drill. By using AI, Earth AI told Business Insider it can cut mineral discovery timelines from years to months. "We think that we can create the most value by drilling into the ground, proving that 'Yes, there are chemical concentrations of metal there,'" said Monte Hackett, CFO of Earth AI. Terra AI is also betting that AI can speed up the industry's slow discovery process. "Despite decades of investment in sensors and data, we're doing worse every year," said John Mern, cofounder and CEO of Terra AI. "The amount of metal added to the global supply this year is 90% lower than it was in 1990." Terra's software uses AI to ingest layers of geological data — like magnetic field readings and seismic activity — used to generate thousands of underground maps to identify the most promising places to drill. Mern said its AI-first approach is already being piloted on rare earth projects in the US and by mining companies across the Americas, Africa, and Europe. He added that Terra's platform could cut the 17-year average mine development timeline in half. Investors see AI applications in mining as a major opportunity. Founders Factory, a UK-based venture firm, recently partnered with mining giant Rio Tinto to launch an accelerator backing 12 startups a year — including Terra AI. Jack Kennedy, an investor at Founders Factory, sees mining as a $2 trillion industry that's been "untouched" by tech innovation. He compares mining to a "waste management business," where tons of earth are moved to extract small amounts of metal. "AI is essentially a way to try and process tons of different data points to make efficiencies," Kennedy told BI. Doing so, he added, translates to reductions in waste, costs, and environmental impact. Legacy players use AI to secure the supply chain Legacy firms are also getting in on the action. Exiger, a supply chain management software provider, helps governments and Fortune 500 companies track and secure critical mineral supply chains. Its AI model breaks down products into digital twins — detailed virtual versions that map the materials inside — then traces the material composition of the products using a database of 10 billion transaction records. The database includes commercial datasets purchased from custom brokers and invoice processes, financial data, engineering specifications, build-to-print drawings, material declarations, and manufacturing process documents. Using AI to assess a company's supply chain gives clients visibility into the vulnerabilities within their mineral supply chains, like where they may be over-reliant on certain countries and geopolitical risks. In turn, clients can make informed decisions when adjusting their mineral supply chain strategy. In one case, Exiger identified how to extract germanium — a rare earth mineral used in fiber optics and chips — from coal ash and smelter waste in the US, potentially reducing foreign dependence. "When China restricted exports on rare earths, it exposed customers to price volatility and geopolitical uncertainty," Brandon Daniels, CEO of Exiger, told BI. "Our platform helps clients navigate that risk with a level of precision previously unattainable." The limitations of AI Still, AI isn't a magic solution. Rajive Ganguli, a mining engineering professor at the University of Utah with decades of experience applying AI in the field, said the technology is only as good as the data it's trained on. High-quality, hard data — like drill hole information and physical samples — is often scarce, expensive, and difficult to obtain. "AI on bad numbers does not result in good answers," Ganguli told BI. He also points out that many "AI discoveries" happen in areas already known to geologists. The technology, he said, doesn't work as well in unexplored, data-poor regions. Additionally, the startups that spoke to BI said that the mining industry remains skeptical about embracing new technologies, making the adoption of AI in the critical mineral discovery process an uphill battle. That said, Ganguli believes the biggest obstacles to scaling up mineral production aren't technological, but systemic. In the US, companies often wait 10 to 15 years to get permits approved. Even though the Trump administration is making moves to fast-track permitting, the process continues to remain bottlenecked in the near term. Despite early talks with US clients, Earth AI hasn't begun exploration in the country due to delays that can drag on for years. Experts agree that AI won't replace humans. Geologists and engineers are still essential for interpreting AI outputs and making final decisions about where to drill. "This isn't a lab problem," Ganguli said regarding mineral discovery, adding that "domain experts" are crucial to understanding how the machines operate, what the data means, and how the site actually works. Even so, companies believe AI can play a key role in strengthening the US mineral supply chain. But even with the best tools, the US is unlikely to do it alone. "The reality is, the majority of our supply chain is going to come from beyond our borders," Terra AI CEO Mern said. "We need responsible international partners to secure it."
Yahoo
13 minutes ago
- Yahoo
Rivian sues to sell its EVs directly in Ohio
Rivian has filed a lawsuit in Ohio to be able sell its electric vehicles directly to consumers in the state — the latest swing in a perpetual fight between up-and-coming American automakers and the entrenched and powerful dealership lobby. The company sued the registrar of Ohio's Bureau of Motor Vehicles (BMV) on Monday in federal court, claiming the state is harming consumers by blocking direct sales. Rivian is currently able to sell EVs directly to consumers in 25 states and in Washington D.C. Ohio's BMV did not immediately respond to a request for comment. 'Ohio's prohibition of Rivian's direct-sales-only business model is irrational in the extreme: it reduces competition, decreases consumer choice, and drives up consumer costs and inconvenience — all of which harm consumers — with literally no countervailing benefit,' lawyers for the company wrote in the complaint. Rivian is asking the court to allow the company to apply for a dealership license so it can sell vehicles directly. Ohio customers have to buy from Rivian vehicles from locations in other states where direct sales are allowed. The cars are then shipped to Rivian service centers within Ohio. Allowing Rivian to sell directly would not be treading new legal ground, the company argues in its complaint. Tesla has had a license to sell in Ohio since 2013 and can sell directly to consumers. What's stopping Rivian is a 2014 law passed by the state's legislature. That law, which Rivian says came after an intense lobbying effort by the Ohio Automobile Dealers Association (OADA), effectively gave Tesla a carve-out and blocked any future manufacturers from acquiring the necessary dealership licenses. (OADA did not immediately return a request for comment.) 'Consumer choice is a bedrock principle of America's economy. Ohio's archaic prohibition against the direct-sales of vehicles is unconstitutional, irrational, and harms Ohioans by reducing competition and choice and driving up costs and inconvenience,' Mike Callahan, Rivian's chief administrative officer, said in a statement. Rivian has won legal fights over direct sales before. In 2021, Rivian and Lucid Motors were granted dealership licenses to sell EVs in the state of Illinois. That state's dealer association sued to try to block Rivian and Lucid from selling directly, but ultimately failed. Lucid Motors, meanwhile, filed a lawsuit of its own in Texas in 2022 in a challenge to that state's direct-sales ban. The court ruled against Lucid earlier this year, but the company has appealed, federal court records show. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.79 billion, while the same for earnings is pinned at 93 cents per share. In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk's 2025 earnings per share (EPS) improved from $3.84 to $3.86. During the same time frame, the company's 2026 EPS forecast has dropped from $4.64 to $4.20. NVO Estimate Movement Image Source: Zacks Investment Research NVO's Earnings Surprise History Novo Nordisk's performance has been mixed over the trailing four quarters, with earnings beating estimates in one quarter, matching once and missing the mark on the remaining two occasions. On average, Novo Nordisk registered an earnings surprise of 0.02% in the trailing four quarters. In the last reported quarter, the company reported EPS that matched estimates. Image Source: Zacks Investment Research What Does Our Model Say? Novo Nordisk has an Earnings ESP of +0.22% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat, which is not the case for NVO. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors Shaping NVO's Upcoming Results Novo Nordisk operates under two segments — Diabetes and Obesity Care and Rare disease. Novo Nordisk reported preliminary earnings per American Depositary Receipt of 91 cents (DKK 5.96) for the second quarter of 2025. During the same period, the company's sales increased 18% at constant exchange rate (CER). On the other hand, operating profit increased 40% at CER in the second quarter of 2025, primarily driven by the ocedurenone impairment charge recognized in the year-ago period. Novo Nordisk's revenues are expected to have been driven by the sale of its diabetes and obesity treatments, particularly semaglutide-based drugs — Wegovy, Ozempic, and Rybelsus. Wegovy is the largest contributor to the company's top line. Its label has also been expanded for cardiovascular benefits in the United States and the EU. Ozempic and Rybelsus sales are also likely to have contributed meaningfully, along with solid insulin product sales. Additionally, the Rare Disease segment is expected to have generated incremental revenues for the company. Novo Nordisk shares tumbled last week after the company slashed its 2025 guidance for both sales and operating profit growth. It now expects sales to increase 8-14%, down from the previous 13-21% range, and operating profit to grow 10-16% compared to the earlier 16-24% estimate. The revision reflects weaker-than-anticipated momentum for key drugs Wegovy and Ozempic, particularly in the U.S. market, where Wegovy is struggling with the continued use of unregulated, compounded GLP-1 alternatives. Despite the FDA ending its compounding grace period in May 2025, illegal semaglutide sales persist under the guise of 'personalized medicine,' prompting NVO to take legal and regulatory action. The company also cited slower-than-expected Wegovy uptake across both insured and cash-pay channels, limited by modest market expansion and growing competition. While efforts through NovoCare and telehealth have spurred some growth, overall adoption remains below expectations. Ozempic is similarly seeing increased competitive pressure in the U.S. diabetes market. International Wegovy rollouts are underway, but demand in certain regions has been slower than projected. On the profit front, Novo Nordisk's lower operating profit outlook is tied to reduced sales expectations, though partially cushioned by cost controls. The updated forecast also reflects a mid-single-digit drag from its acquisition of three Catalent manufacturing sites. NVO's Stock Price & Valuation Year to date, Novo Nordisk shares have lost 44% compared with the industry's 5% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a discount to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 11.87 forward earnings, which is lower than 14.28 for the industry. The stock is also trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Investment Thesis Novo Nordisk's stock decline in 2025 has been driven by a mix of regulatory setbacks, underwhelming pipeline results, and rising competitive pressure. The company reported weaker-than-expected data from two late-stage studies of CagriSema, its next-generation obesity drug, dampening hopes for a strong follow-up to Wegovy. In addition, Medicare's refusal to cover weight-loss drugs like Wegovy — since obesity is not classified as a disease — has raised concerns over patient access. The situation is further complicated by an ongoing leadership change, with CEO Lars Fruergaard Jørgensen stepping down amid market headwinds and stock underperformance. Moreover, Novo Nordisk faces intense competition from its arch-rival Eli Lilly LLY in the diabetes and obesity care market. LLY markets its tirzepatide injections as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Zepbound had earlier outperformed Novo Nordisk's Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study. This could lead to a shift in patient preference from Wegovy to Zepbound, potentially resulting in a loss of market share. Lilly has also been taking significant strides in the development of oral therapies for obesity, effectively putting pressure on Novo Nordisk. In April 2025, LLY reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in T2D patients. Oral pills could boost adherence over injections. Several other companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and T2D, with the first two phase III studies initiated in March. Viking Therapeutics started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. A mid-stage study is currently ongoing, evaluating an oral version of this obesity drug, with a data readout expected later this year. Additionally, NVO recently ended its collaboration agreement with Hims & Hers Health, which will temporarily hurt its objective of increasing Wegovy's patient access, resulting in a slowdown in obesity market share gain. Furthermore, the presence of compounded versions of Wegovy in NVO's largest obesity market, the United States, is weighing in on the sales potential of the drug, eating away at its revenues. Despite recent setbacks, Novo Nordisk is making steady progress across its pipeline. The company is advancing new candidates for T2D and obesity, while also working to expand the approved uses of Wegovy, Ozempic and Rybelsus to drive further growth. Efforts to develop next-generation obesity drugs could help diversify its portfolio. Beyond metabolic diseases, NVO is also building out its rare disease segment, with late-stage progress on Mim8 for hemophilia A and recent FDA approval of a broader label for its Alhemo injection for hemophilia A or B with/without inhibitors, further strengthening its position in the hemophilia space. Here's How to Play NVO Stock Amid growing challenges, we believe investors might want to reduce their exposure to Novo Nordisk, regardless of how its second-quarter results turn out. While the company is still seeing solid demand and revenue growth from its semaglutide-based drugs, it recently cut its 2025 sales and profit forecast due to slowing momentum in key markets. In the United States, sales of Wegovy and Ozempic are being hurt by the continued use of compounded versions, even after FDA restrictions. At the same time, rival Eli Lilly is gaining ground with its competing drugs, Zepbound and Mounjaro, which have shown stronger clinical results and are quickly gaining market share, putting pressure on Novo Nordisk's core business. Adding to the headwinds, the stock has underperformed significantly in 2025 and now trades at a steep discount to both its historical average and the broader industry. Disappointing data from CagriSema studies and a major CEO transition amid a turbulent period have further shaken investor confidence. While the long-term potential in obesity and rare diseases remains, heightened volatility, pipeline disappointments, legal and regulatory challenges, and a crowded GLP-1 development landscape suggest that the near-term risk/reward profile is skewed to the downside. These factors may prompt risk-averse investors to consider exiting their position or limiting exposure until clearer visibility emerges. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
